Faculty Collaboration Database

1. Lee VK, See WA, Hellstrom I, Hellstrom KE: An immunotherapeutic model for murine transitional cell carcinoma. Immunity to Cancer. Academic Press, 1985, pages 387-391.

2. See WA, Chapman WH: Tumor cell implantation following neodymium-YAG bladder injury: A comparison to electrocautery injury. J Urol 137:1266-1269, 1987.

3. See WA, Chapman PH: Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. J Urol 138:182-186, 1987.

4. Chou CK, See WA, Luk KH, Chapman WH: Microwave hyperthermia system for treating bladder carcinoma in rats. Endocuriether Hyperther Oncol 3:147, 1987.

5. See WA, Mack LA, Krieger JK: Scrotal ultrasonography: A predictor of complicated epididymitis requiring orchiectomy. J Urol 139:55-56, 1988.

6. See WA, Miller JS, Williams RD: Pathophysiology of transitional tumor cell adherence to sites of urothelial injury: Mechanisms mediating intravesical recurrence due to implantation. Cancer Res 49:5414-5418, 1989.

7. See WA, Chapman PH, Williams RD: Kinetics of transitional tumor cell line 4909 adherence to injured urothelial surfaces in (F-344) rats. Cancer Res 50:2499-2504, 1990.

8. See WA, Taylor TO, Mack LA, Tartaglione TA, Opheim KE, Berger RE: Bacterial epididymitis in the rat: A model for assessing the impact of acute inflammation on epididymal antibiotic penetration. J Urol 144:780-784, 1990.

9. Abdel-Nabi HH, Ortman-Nabi JA, See WA, Lee J, Ireton R, Boileau M, Unger MW, Halverson C: Clinical experience with intra lymphatic administration of [111In]-labeled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma. Eur J Nucl Med 16:149-156, 1990.

10. See WA, Smith JL: Activated proteolytic enzymes in the urine of whole organ pancreas transplant patients with duodenocystostomy. Transplant Proc 23:1615-1616, 1991.

11. Smith JL, See WA, Ames SA, Piper JB, Corry RJ: Lower urinary tract complications in patients with duodenocystostomies for exocrine drainage of transplanted pancreas. Transplant Proc 23:1611-1612, 1991.

12. See WA, McDermott T, Xia Q, Williams RD: A continuous intravesical drug delivery system for the rat. J Urol 145:596-599, 1991.

13. See WA, Mayo M: Ectopic ureter: a rare cause of purulent vaginal discharge. Obstet Gynecol 78:552-555, 1991.

14. See WA, Crist SA, Boileau MA, Williams RD: Single-dose preoperative systemic cyclophosphamide for the prevention of bladder tumor implantation in F-344 Rats. Cancer Res 51:1373-1377, 1991.

15. See WA, Crist SA, Williams RD: Single-dose cyclophosphamide for the prevention of bladder tumor implantation in F-344 rats: Site of drug activity. Cancer Res 51:1378-1383, 1991.

16. Dreicer R, See WA, Williams RD: Current controversies in urologic oncology. Iowa Med 81:343-345, 1991.

17. See WA, Smith JL: Urinary levels of activated trypsin in whole organ pancreas transplant patients with duodenocystostomies. Transplantation 52:630-633, 1991.

18. See WA, Xia Q, McDermott T, Williams RD: Regional chemotherapy using Continuous infusion adriamycin for the treatment of muscle invasive transitional cell bladder carcinoma in a rat model. J Urol 146:1147-1152, 1991.

19. Winfield HN, Donovan JF, See WA, Loening SA, Williams RD: Urologic laparoscopic surgery. State of the Art Article. J Urol 146:941-948, 1991.

20. Tartaglione TA, Taylor TO, Opheim KE, See WA, Berger RD: Antimicrobial tissue penetration in a rat model of E. coli epididymitis: preliminary observations. J Urol 146:1413-1417, 1991.

21. Beer SJ, See WA: Intracorporal needle breakage: an unusual complication of papaverine injection therapy for impotence. J Urol 147:148-149, 1992.

22. See WA, Williams RD: Urothelial injury and clotting cascade activation: Common denominators in particulate adherence to urothelial surfaces. J Urol 147:541-548, 1992.

23. See WA, Rohlf DP, Crist SA: In vitro particulate adherence to fibronectin: Correlation with in vivo particulate adherence to sites of bladder injury. J Urol 147:1416-F3, 1992.

24. Cooper C, See WA: The impact of iatrogenic urothelial trauma on urinary levels of transforming growth factor-alpha. J Urol 147:1647-1649, 1992.

25. See WA, Xia Q: Regional chemotherapy for bladder neoplasms using continuous intravesical infusion doxorubicin: impact of concomitant DMSO administration on drug absorption and anti-tumor activity. J Nat'l Cancer Inst 84:510-515, 1992.

26. See WA: Intravesical recombinant tissue plasminogen activator for the prevention of implantation mediated bladder tumor recurrence. Clin Exp Metast 10:99-109, 1992.

27. See WA, Williams RD: Tumors of the kidney, ureter, and bladder. West. J Med 156:523-534, 1992.

28. See WA, Fuller J: Staging of advanced bladder cancer: current concepts and pitfalls. Urol Clin N Am 19:663-683, 1992.

29. See WA: New concepts in the treatment of superficial urothelial cancer - Part 1. Surg Rounds 15:805-808, 1992.

30. See WA: New concepts in the treatment of superficial urothelial cancer - Part 2. Surg Rounds 15:897-902, 1992.

31. Winfield HW, Donovan JF, See WA, Loening SA, Williams RD: Laparoscopic pelvic lymph node dissection for genitourinary malignancies: Indications, techniques, and results. J Endourol 6:103-111, 1992.

32. See WA: Laparoscopy: The "non-cutting" edge of urologic surgery. Symposium: modern methods of sonography and laser therapy in urology. Bierman Verlag GMBH 103-110, 1992.

33. See WA, Smith JL: Urinary trypsin levels observed in pancreas transplant patients with duodenocystostomies promote in vitro fibrinolysis and in vivo bacterial adherence to urothelial surfaces. Urol Res 20:409-413, 1992.

34. Betz SA, See WA, Cohen MB: Granulomatous inflammation in bladder wash specimens following intravesical Bacillus Calmette-Guerin therapy for transitional cell carcinoma of the bladder. Am J Clin Path 99:244-248, 1993.

35. See WA, Cohen MB, Hoxie LD: Alpha-fetoprotein half-life as a predictor of testicular tumor: effect of the analytic strategy on test sensitivity and specificity. Cancer 71:2048-2054, 1993.

36. See WA, Fisher RL, Winfield HN, Donovan JF: Laparoscopic surgical training: effectiveness and impact on urologic surgical practice patterns. J Urol 149:1054-1057, 1993.

37. See WA, Cohen MB, Winfield HN: Inverted V peritoneotomy significantly improves nodal yield in laparoscopic pelvic lymphadenectomy. J Urol 149:772-775, 1993.

38. See WA, Hoxie LD: Chest staging in testes cancer patients: imaging modality selection based upon risk assessment as determined by abdominal CT scan results. J Urol 150:874-878, 1993.

39. See WA: Plasminogen activators: regulators of tumor cell adherence to sites of lower urinary tract surgical trauma. J Urol 150:1024-1029, 1993.

40. See WA: Superficial bladder tumor recurrence gaining attention. Urol Times 21:14-20, 1993.

41. See WA, Cooper CS, Fisher RJ: Predictors of laparoscopic complications following formal training in laparoscopic surgery. JAMA 270:2689-2692, 1993.

42. See WA, Cooper CS, Fisher RJ: Urological laparoscopic practice patterns 1 year following formal training. J Urol 151:1595-1598, 1994.

43. See WA, Yong X, Crist S, Hedican S: Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines. J. Urol 151:1691-1696, 1994.

44. See WA: Prostate cancer therapy: a recipe for confusion. Iowa Med 84:255-258, 1994.

45. Xu Y, See WA: Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors. Surg Oncol 3:175-185, 1994.

46. See WA, Cooper C, Fisher R: Complication rates associated with the introduction of new technology into the clinical health care setting correlate with operator experience and training. Proceedings: International Society for Optical Engineering. 2307:360-365, 1994.

47. See WA: Laparoscopy at the crossroads (editorial). J Urol 152:1193, 1994.

48. See WA: Commentary on growth factors: The bread-and-butter cytokines of urology. J Urol 152:1942, 1994.

49. Lyon PB, See WA, Xu Y, Cohen MB: Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Prostate 27(4):179-186, 1995.

50. See WA, Fuller JR, Toner ML: An outcome study of patient-controlled morphine analgesia, with or without ketorolac, following radical retropubic prostatectomy. J Urol 154(4):1429-1432, 1995.

51. Terrell RB, Cheville J, See WA, Cohen MB: Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis. J Urol 154(4):1342-1347, 1995.

52. See WA, Dreicer R, Boatman D, Hussey D, Milleman L, Rohlf P, Rosenberg S, Anderson M, Haas AC, McGuire A, Morton R, Overson P, Wilson M, Schulte M, Kresowik T: Prostate cancer management in older patients. Iowa Med 85:489-490, 1995.

53. See WA: Council-tip catheter facilitates vesicourethral anastomotic suture placement. Urology 46(3):401-402, 1995.

54. See WA. Prostate Cancer Management in older patients. Iowa-Med. 85(12); 489-90, 1995.

55. See WA, Laurenzo JF, Dreicer R, Hoffman HT: Incidence and management of testicular carcinoma metastatic to the neck. J Urol 155(2):590-592, 1996.

56. See WA: Radical cystectomy: cornerstone or millstone? (editorial). J Urol 155:504-505, 1996.

57. See WA, Dreicer R, Wheeler JA, Forest PK, Loening S. Brachytherapy and continuous infusion 5-fluorouracil (5-FU) for the treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. Cancer 77(5):924-927, 1996

58. See WA, Kresowik TF, Jochimsen PR: Peritoneal venous shunting for the treatment of lymphatic ascites following retroperitoneal lymph node dissection. Urology 48(5):783-785, 1996.

59. See WA: Expert opinion: Transitional cell carcinoma, case history. Urol Int 3:6-7, 1996.

60. Dreicer R, Gustin D, See WA, Williams RD: Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 156(5):1606-1608, 1996.

61. Sarosdy MF, Lowe BA, Schelhammer PF, Lamm DL, Graham SD, Grossman HB, See WA, et al. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 48:21-27, 1996.

62. Callaghan EJ, See WA, Dreicer R, Cohen MB. Cytologic changes associated with intravesical Adriamycin therapy for invasive transitional cell carcinoma (TCC) of the bladder. Modern Path. 9(1): 32A, 1996.

63. Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WA: A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. Cancer Invest, 15:311-317, 1997.

64. Habboub HK, Abu-Yousef MM, Williams RD, See WA: Accuracy of color doppler sonography in assessing venous thrombus extension in renal cell carcinoma. AJR-Am J Roentgenol 168(1):267-271, 1997.

65. See WA, Xu Y, Gee K, Severson CD, Cohen MB, Ladehoff D: Transurethral bladder tumor resection alters fibronectin expression in transitional carcinoma cell lines. J Urol 157(3):1136-1143, 1997.

66. See WA, Berman CJ: Future therapies for treatment of bladder neoplasms. Semin Surg Oncol 13(5):376-388, 1997.

67. Lund GO, Winfield HN, Donovan JF, See WA, Loening SA, Williams RD. Laparoscopic pelvic lymph node dissection following definitive radiotherapy for carcinoma of the prostate. J Urol 157(2):548-551, 1997.

68. Porter MP, Ahaghotu CA, Loening SA, See WA: Disease-free and overall survival after cryosurgical monotherapy for clinical stages B and C carcinoma of the prostate: a 20-year follow-up. J Urol 158(4):1466-1469, 1997.

69. Dreicer R, Galbriath SS, Davis CS, See WA: Surgical resection of metastatic renal cell carcinoma: The University of Iowa experience. Urol Oncol 3(3):99-101, 1997.

70. Griebling TL, Ozkutlu D, See WA, Cohen MB: Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Mod Pathol 10(8):804-809, 1997.

71. See WA, Dreicer R, Forest PK, Riggs C: Continuous infusion, intravesical doxorubicin for the treatment of regionally advanced bladder cancer: a phase I-II trial. Am J Clin Oncol 20(4):331-337, 1997.

72. Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WA. A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. Cancer Invest. 15 (4):311-7, 1997.

73. Zhang G-J, Ladehoff D, Xu Y, See WA: Stable overexpression of TGFbeta1 in a transitional carcinoma cell line: impact on fibronectin production. J Urol 160(1):230-235, 1998.

74. Burns JA, Kreder KJ, Lubaroff DM, See WA: Alterations in constituent urinary proteins in response to bladder outlet obstruction in rats. J Urol 159(5):1747-1751, 1998.

75. Mulholland TL, See WA: Pledgeted sutures for parenchymal compression facilitate partial nephrectomy. Br J Urol 81(4):630-633, 1998.

76. See WA: Letter to the editor: Hudson MA, McReynolds LM: Urokinase and the urokinase receptor: Association with in vitro invasiveness of human bladder cancer cell lines. JNCI 90(17):1303, 1998.

77. Colegrove PM, Winfield HN, Donovan JF, See WA: Laparoscopic practice patterns among North American urologists 5 years after formal training. J Urol 161(3):881-886, 1999.

78. Dreicer R, Smith DC, Williams RD, See WA: Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest New Drugs 17(2):183-6, 1999.

79. Zayyan K and See WA. Letter to the editor: Their initial experience with laparoscopy-assisted cystectomy. W J Surg Oct;24(10):1282-3, 2000.

80. See WA. Distal Ureteral Regeneration after Radical Transurethral Bladder Tumor Resection. Urol. 55(2):212-5; discussion 215-6, 2000.

81. Zhang G, Crist SA, McKerrow A, Xu Y, Ladenfoff D, See WA. Autocrine IL-6 Production by Human Transitional Carcinoma Cells Upregulates Expression of the alpha5beta1 fibronectin receptor. J Urol. 163(5):1553-9, 2000.

82. See WA: Continuous antegrade infusion adriamycin as adjuvant therapy for upper tract urothelial malignancies. Urol 56(2):216-22, 2000.

83. Bianchi GD, Cerhan JR, Parker AS, Putnam SD, See WA, Lynch CF, Cantor KP. Tea Consumption and Risk of Bladder and Kidney Cancers in a Population-based Case-Control Study. Am J Epidemiology; 151(4): 377-83, 2000.

84. Langenstroer P, See WA. The role of a second transurethral resection for high-grade bladder cancer. Current Urology Reports. 1(3):204-7, 2000 Oct.

85. Siemens DR, Iwasawa T, Austin JC, Williams RD, See WA, Hedican SP, Tartaglia J, Flynn CM, Cohen MB, Rodgers J, Ratliff TL: Biomarker distribution after injection into the canine prostate: implications for gene therapy. Br J Urol Dec; 86(9):1076-83, 2000.

86. McLeod D, See W, Iversen P, Wirth M, Beckman R, Carroll K: Tolerability of bicalutamide ('Casodex" 150mg) as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. J Urology 2001; 165(5).

87. See W, McLeod D, Iversen P, Wirth M. The Casodex (Bicalutamide) Early prostate cancer program: final demographic data. Urol Oncol: 6(2); 43-47, 2001

88. See W, McLeod D, Wirth M, Iversen P, Persson B-E, Carroll K. Bicalutamide ('Casodex' 150 mg) as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. J Urol 165(5), 2001

89. Tyrrell C, Payne H, Wirth M, Iversen P, See W, McLeod D, Persson B-E, Carroll K. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in localized or locally advanced prostate cancer. Eur J Cancer 37 suppl 6, 2001.

90. See WA. Commentary: "Imaging Prostate Cancer: Current and Future Applications" Oncology 15(3) 339, 2001.

91. Siemens DR, Austin JC, See WA, Tartaglia J, Ratliff TL. Evaluation of gene transfer efficiency by viral vectors to murine bladder epithelium. J. Urol. 165 (2); 667-71, 2001.

92. Dreicer, R, See WA, Klein EA. Phase II Trial of GM-CSF in Advanced Prostate Cancer. New Drugs 19 (3):261-265, Aug 2001.

93. Sueppel C, Kreder K, See WA. Improved continence outcomes with preoperative pelvic floor muscle strengthening exercises. Urologic Nursing. 21(3): 201-10, 2001 Jun.

94. Chen F-H, Crist SA, Zhang G-J, Iwamoto Y, See WA. Interleukin-6 production by human bladder tumor cell lines is up regulated by BCG through NF-b and AP-1 via an immediate early pathway. J. Urol. 168:786-797, 2002.

95. See WA, Wirth M, McLeod D, Iverson P: Bicalutamide ('Casodex') 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol. 168:429-435, 2002.

96. Wirth M, Iversen P, McLeod D, See W: Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide ('Casodex') EPC Programme. Eur Urol Supplement. 1(7):20-25, 2002

97. See W: PSA Changes in Early Prostate Cancer: Implications for Patient Management. Eur Urol Supplement. 1(5):17-23, 2002

98. Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson Jr, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group. Is the efficacy of hormonal therapy affected by lymph node status? New data from the bicalutamide EPC programme. Eur Urol 1(1)528, 2002.

99. Iversen P, Wirth M, See W, McLeod D, Morris T, Carroll K. Is the efficacy of hormonal therapy affected by lymph node status? New data from the bicalutamide EPC programme. J Urology 167(4), 2002

100. See W, McLeod D, Wirth M, Iversen P, Persson B-E, Carroll K. Bicalutamide ('Casodex') 150 mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. Prostate Cancer and Prostatic Diseases 5(1) 71-72, 2002.

101. See W, Wirth M, McLeod D, Iversen P, Persson B-E, Carroll K on behalf of the 'Casodex' Early Prostate Cancer Trialists' Group. Immediate treatment with bicalutamide reduces the risk of disease progression in early non-metastatic prostate cancer irrespective of primary therapy. Eur Urol 1(1)533, 2002.

102. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace M, Delaere K, Vaage S, Tammela T, Lukkarinen O, Persson B-E, Carroll K, Kolvenbag G on behalf of the 'Casodex' Early Prostate Cancer Trialists' Group. Bicalutamide ('Casodex') 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 168:429-435, 2002.

103. Vaughn DJ, Manola J, Dreicer R, See WA, Levitt R, Wilding G. Phase II study of Paclitaxel plus carboplatin in patients with advanced carcinoma of the Urothelium and renal dysfunction (E2896): a trail of the Eastern Cooperative Oncology Group. Cancer. 96(5):1022-7, 2002 Sep 1

104. Chen F, Langenstroer P, Zhang G, Iwamoto Y, See WA. Androgen Dependent Regulation of Bacillus Calmette Guerin Induced Interleukin-6 Expression in Human Transitional Carcinoma Cell Lines. J Urol 170(5):2009-13, 2003.

105. See WA. Adjuvant Hormone Therapy for Localized or Locally Advanced Prostate Cancer. Current Treatment Options in Oncology 4(5):351-62, 2003.

106. Payne H, Terrell C, See WA, McLeod DG, Wirth MP, Iverson P, Garside L. Bicalutamide 150 mg as Adjuvant to Radiotherapy Significantly Increases Progression Free Survival in Early Prostate Cancer. Int J of Rad Onc Biol, Physics 57(2 suppl)5173-4, 2003.

107. Chen FH, Zhang GJ. Iwamoto Y. See WA. BCG Initiates Intracellular Signaling in a Transitional Carcinoma Cell Line by Crosslinking 51 Integrin. J. Urol. 170:605-10, 2003.

108. See WA, Iverson P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with Bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology. 44(5):512-7; discussion 517-8, 2003 Nov

109. See WA. Bicalutamide Adjuvant to Radical Prostatectomy. Reviews in Urology 6(2):S20-28, Spring 2004.

110. Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III Trial of Methotrexate, , Vinblastine, Doxorubicin, and Cisplatin Versus Carboplatin and Paclitaxel in Patients with Advanced Carcinoma of the Urothelium. Cancer Apr 15; 100(8):1639-45, 2004.

111. Rydberg JN, Sudakoff GS, Hellman RS, See WA. Positron Emission Tomography-Computed Tomography Imaging Characteristics of an Inferior Vena Cava Tumor Thrombus with Magnetic Resonance Imaging Correlation. J Comput Assis Tomogr 28(3):1-3, May/June 2004.

112. Zhang G, Chen F, Xu T, Cao Y, Crist S, McKerrow A, Iwamoto Y, See WA. Autocrine over expression of fibronectin by human transitional carcinoma cells impairs bacillus Calmette-Guerin adherence and signaling. Journal of Urology. 172(4Pt 1):1496-500, 2004 Oct.

113. Wirth MP, See WA, McLeod DG, Iverson P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer; results from the second analysis of the early prostate cancer program as median followup of 5.4 years. Journal of Urology. 172(5 Pt 1): 1865-70, 2004 Nov.

114. Sudakoff GS, Guralnick M, Langenstroer P, Foley WD, Cihlar KL, Shakespear JS, See WA. CT Urography of Urinary Diversions with Enhanced CT Ditital Radiography: Preliminary Experience. 184:131-138. Am J Rad 2005 Jan

115. Chen F, Zhang G, Iwamoto Y, See WA. BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urology, 5(1):8, 2005 May 12.

116. Zhang G, Li Y, Xu Y, See WA. Micro Array Analysis of the Effect of Post-TURBT Urine on TGFB1 Dependent Gene Regulation in a Transitional Carcinoma Cell Line. Urologic Oncology 23(6) 413-8, 2005 Nov

117. Nithipatikom K, Isbell MA, See WA, Campbell WB. Elevated 12- and 20-hydroxyeicosatetraeonic acid in urine of patients with prostatic diseases. Cancer Letters 233(2) 219-25, 2006 Feb

118. McLeod, D, Iverson, P, See, WA, Morris, T, Armstrong, J, Wirth, M, CASODEX Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus Standard Care vs Standard Care Alone for Early Prostate Cancer. BJU International. 97(2):247-54. 2006 Feb

119. Gray, R, Manola, J, Saxman, S, Wright, J, Dutcher, A, Atkins, M, Carducci, M, See, WA, Sweeney, C, Liu, G, Stein, M, Dreicer, R, Wilding, G, DiPaola, R.. Phase II clinical trial design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group, Clinical Research Center, 12(7 Pt1):1966-9, 2006 Apr 1

120. Lawatsch, E, Langenstroer, P, Byrd, G, See, WA, Quiroz, F, Begun, F. Intermediate Results of Laparoscopic Cyroablation in 59 patients at the Medical College of Wisconsin. Journal of Urology. 175(4):1225-9. 2006 Apr

121. McLeod, D, See, WA, Klimberg, I, Gleason, D, Chodak, G Montie, J, Bernstein, G, Morris, C, Armstrong, J. The Bicalutamide 150 mg early Prostate Cancer Program: Findings of the North American trial at 7.7 year median follow-up. Journal of Urology. 176(1):75-80, 2006 Jul

122. Warren, K. Chodak, G, See, WA, Iverson, P, McLeod D, Wirth, M, Morris, C, Armstrong, J. Are Bone Scans Necessary in Men with Low Prostate Specific Antigen Levels following Localized Therapy? Journal of Urology. 176(1):70-3. 2006 Jul

123. See, WA. Tyrrell, C. CASODEX Early Prostate Cancer Trialists' Group. The Addition of Bicalutamide 150 mg to Radiotherapy Significantly Improves Overall Survival in Men with Locally Advanced Prostate Cancer. Journal of Cancer Research & Clinical Oncology. 132 Suppl 1:S7-16, 2006 Aug

124. Smither, A, Guralnick, M, Davis, N, See, WA. Quantifying the Natural History of Post-Radical Prostatectomy Incontinence using Objective pad test data. BMC Urology, 7:2, 2007

125. Zhang G, Chen F, Cao Y See, WA. BCG Induces P21 Expression in Human Transitional Carcinoma Cell Lines via an Immediate-Early, P53 Independent Pathway. Urologic Oncology 25(3)221-7, 2007

126. Chen F, Zhang G, Cao Y, Payne R, See WA Bacillus Calmette-Guerin Inhibits apoptosis in Human Urothelial Carcinoma Cell Lines in Response to Cytotoxic Injury. Journal of Urology 178(5)2166-70, 2007

127. Sudakoff GS, See WA. Multidetector CT Urography as the Primary Imaging Modality for Detecting Urinary Tract Neoplasms in Patients with Asymptomatic Hematuria. Journal of Urology, 2008, 179(3) 862-7

128. See WA, Zhang G, Chen F, Cao Y, Langenstroer P, Sandlow J. BCG Induces Caspase-Independent Cell Death in Urothelial Carcinoma Cells Together with Release of the Necrosis-Associated Chemokine HMGB1; BJU- 103(12)1714-1720, June 2009

129. Li R and See WA: SmgGDS is unregulated in prostate carcinoma and promotes tumor phenotypes in prostate cancer cells; The Journal of Pathology, 217:389.97, 2009

130. See WA, Garg T: Bladder Neck Contracture Following Radical Retropubic Prostatectomy Utilizing an Intussuscepted Vesicouretheral Anastomosis: Incidence with Long Term Follow Up. BJU International 104(7)925-928, October 2009

131. Garg T, Guralnick ML, Langenstroer P, See WA, Hieb RA, Rilling WS, Sudakoff SG, O'Connor RC: Resonance® metallic ureteral stents do not successfully treat ureteroenteric strictures in patients with ileal conduits. J Endoural. July 2009

132. Chen F, Zhang G, Cao Y, Hessner MJ, See WA: The MB49 Murine Urothelial Carcinoma:A Molecular and Phenotypic Comparison to Human Cell Lines as a Model for Studying the Direct Tumor Response to BCG. Journal of Urology, 2009 181(4)412 April 2009

133. Mesrobian H G, Mitchell M E, See W A, Halligan B D, Carlson B E, Greene A S, Wakim B T: Candidate Urinary Biomarker Discovery in Ureteroplevic Junction Obstruction: A Proteomic Approach. The Journal of Urology, 184(2): 709-14, Aug 2010

134. See WA, Zhang G, Chen F, Cao Y. p21 Expression by Human Urothelial Carcinoma Cells Modulates the Phenotypic Response to BCG. Urologic Oncology. 28(5): 526-33, Sept-Oct, 2010

135. Iverson P, See WA: Antiandrogen Monotherapy in Patients with Localized or Locally Advanced Prostate Cancer:Final Results from the Bicalutamide (Casodex) Early Prostate Cancer Program me at 9.7 years' median follow-up. BJUI; 105 (1074-1081) 2010

136. See WA. RE: Comparative Effectiveness of Prostate Cancer Surgical Treatments: A Population Based Analysis of Postoperative Outcomes: W.T. Lowrance, E.B. Elkin, L.M. Jacks, D. S. Yee, T. L. Jang, V.P. Laudone, B.D. Guillonneau, P.T. Scardion and J.A. Eastham J Urol 2010; 183: 1366-1372. Journal of Urology, 184(4):1573-4; author reply 1574, Oct 2010 (comment letter)

137. Guise A, Chen F, Zhang G, See WA. The Effects of Physiological Estrogen Concentration on the Immune Response of Urothelial Carcinoma Cells to Bacillus Calmette-Guerin. Journal of Urology. 185(1):298-304, Jan 2011

138. Neff DA, See WA: Laparoscopic Mesh Herniorraphy: Impact on Outcomes Associated with Radical Retropubic Prostatectomy. Urologic Oncology, 29 (1) 66-9, 2011 Jan- Feb

139. Patch S, Eckhart E, Balmer, See WA;Ex Vivo Thermoacoustic Imaging over Large Fields of Views with 108 MHz Irradiation. TBME-00923-2010 Trans Biomedical Engineering, March 17, 2011

140. Kriegel A, Liu Y, Mladinov D, Cohen B, Usa K, Kelly H, Langenstroer P, See WA, Liang M. MicroRNA miR-382 targets (chymo) Trypsin-like Proteinase Kallikrein 5 and Contributes to the Development of Renal Interstitial Fibrosis. Journal of Clinical Investigation (submitted)

1. See WA, Ignatoff J: Intravesical Therapy for Superficial Bladder Cancer, Authors: Baselli EC, Greenberg RE: J Oncology Volume 14 Number 5.

2. See WA, Perez CA: Imaging Prostate Cancer: Current and Future Applications, Authors: Gomella LG, El-Gabry EA, et al: Oncology Volume 15 Number 3.

3. See WA: Intravesical Gemcitabine for Multifocal Carcinoma-in Situ (CIS) in Immunocompromised Patients: Case Review and Report of Literature. In Urologic Oncology: Seminars and Original Investigations

4. See WA: Editorial comment: Ovesen H, et al: The long-term efficacy of intravesical BCG treatment of carcinoma in situ: relation of progression to histological response and p53 nuclear accumulation. J Urol 157:1659, 1997

5. See WA: Editorial comment: Theodorescu D, et al: P53, Bc1-2 and Rb proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158:137, 1997.

6. See WA: Editorial comment: Zlotta AR, et al: Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of Bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol 157:498, 1997.

7. See WA. Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients Botto H, Sebe P, Molinie V, Herve JM, Yonneau L, Lebret T, Department of Urology, Hopital Foch, Suresnes, France. Urologic Oncology. 23(3):219, 2005 May - Jun

8. See WA. Interim results from a national multicenter phase II trail of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer O'Donnell MA, Lilli K, Leopold C, National Bacillus Calmette0Guerin/Interferon Phase 2 Investigator Group, Department of Urology, University of Iowa, Iowa City, IA. Urological Oncology. 23(3):218, 2005 May-Jun.

9. See WA. Urethral recurrence in patients following orthotopic urinary diversion Hassan JM, Cookson MS, Smith JA Jr, Chasubng SS, Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN. Urologic Oncology. 23(3):219-20, 2005 May-Jun.

10. See WA. Olfactory detection of human bladder cancer by dogs; proof of principle study Willis CM, Church SM, Guest CM, Cook WA, McCarthy N, Bransbury AJ, Church MR, Church JC, Department of Dermatology, Amersham Hospital, Amersham, United Kingdom. Urologic Oncology. 23(3):217, 2005 May - Jun.

11. See WA. Holmium:YAG laser vaporization of recurrent papillary tumours of the bladder under local anesthesia Jonler M, Lund L, Bisballe S, Division of Urology, Department of Surgery, Viborg Hospital, Viborg, Denmark. Urologic Oncology. 23(3):217-8, 2005 May - Jun

12. See WA: Editorial, Herr HW: Urachal carcinoma: the case for extended partial cystectomy. In deKernion, JB (ed): Year Book of Urology. Chicago: Mosby-Year Book, Inc. 1995.

13. See WA: Editorial, Kiemeney LALM et al: Should random urothelial biopsies be taken from patients with primary superficial bladder cancer: a decision analysis. In deKernion, JB (ed): Year Book of Urology. Chicago: Mosby-Year Book, Inc. 1995.

14. See WA: Editorial, Vikram B et al: A pilot study of chemotherapy alternating with twice a day accelerated radiation therapy as an alternative to cystectomy in muscle infiltrating (stages t2 and t3P)cancer of the bladder: preliminary results. In deKernion, JB (ed): Year Book of Urology. Chicago: Mosby-Year Book, Inc. 1995.

15. See WA: Editorial, Herr HW et al: Intravesical Bacillus Celmette-GuÈrin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. In deKernion JB (ed): Year Book of Urology. St. Louis: Mosby-Year Book, Inc. 1996.

16. See WA: Editorial, Aso Y et al: Preventive effect of a lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. In deKernion JB (ed): Year Book of Urology. St. Louis: Mosby-Year Book, Inc. 1996.

17. See WA: Editorial, Sarosdy MF, et al: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. In deKernion JB (ed): Year Book of Urology. St. Louis: Mosby-Year Book, Inc. 1996.

18. See WA: Editorial, Holmang S, et al: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. In deKernion JB (ed): Year Book of Urology. St. Louis: Mosby-Year Book, Inc. 1996.

19. See WA: Editorial, Bouffioux C, et al: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma. In deKernion JB (ed): Year Book of Urology. St. Louis: Mosby-Year Book, Inc. 1996.

20. See WA: Editorial, Carreon T, et al: NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Urologic Oncology. 24(3), 273 May-June 2006

21. See WA: Editorial, Liedberg F, et al: Treatment delay and prognosis in invasive bladder cancer. Urologic Oncology. 24(3), 274 May-June 2006

22. See WA: Editorial, Grossman HB, et al: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Urologic Oncology. 24(3), 274-5 May-June 2006

23. See WA: Editorial, Lehmann J, et al: Complete long term survival data from a trial of adjuvant chemotherapy vs control after radical Cystectomy for locally advanced bladder cancer. Urologic Oncology. 24(3), 275-6See, May-June 2006

24. See WA: Editorial, Andius P, et al: Intravesical bacillus Calmette-Guérin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects. Urologic Oncology. 24(3), 276 May-June 2006

25. See WA: Editorial, Smaldone MC, et al: Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urologic Oncology. 27(3):343, May-June 2009

26. See WA: Editorial, Guzzo TJ, et al: Outcomes of Patients after Aborted Radical Cystectomy for Intraoperative findings of Metastatic Disease. Urologic Oncology. 27(3):342-3 May-June 2009

27. See WA: Editorial, Rao PK, et al: Routine Perioperative Chemotherapy Instillation with Initial Bladder Tumor Resection Urologic Oncology. 27(3):341-2, May-June 2009

28. See WA: Editorial, Berglund RD, et al: An analysis of the Effect of Statin use on the Efficacy of Bacillus Calmette-Guerin Treatment for Transitional Cell Carcinoma of the Baldder. Urologic Oncology. 27(3):340-1, May-June 2009

29. See WA, Williams RD: Ureterectomy. In Fowler JE, Jr., (ed): Mastery of Surgery: Urology. Boston: Little, Brown and Co., 1992.

30. See WA: Selection and Preparation of the Patient for Laparoscopic Surgery. In Clayman RV, McDougall EM (eds): Laparoscopic Urology. St. Louis: Quality Medical Publishing, Inc., 1993.

31. See WA, Monk TG, Weldon BC: Complications of Laparoscopy: Strategies for Prevention and Treatment. In Clayman RV, McDougall EM (eds): Laparoscopic Urology. St. Louis: Quality Medical Publishing, Inc., 1993.

32. See WA: Complications of Urologic Laparoscopy. In Winfield HN, Gommela L, Kozminski HN (eds): Laparoscopic Urologic Surgery. New York: Raven Press, 1993.

33. See WA: Complications of Laparoscopy: Strategies for Avoidance and Management. In Fahlenkamp D, Loening SA (ed): Laparoscopische Urologie. Berlin: Blackwell Wissenschaft, 1993.

34. See WA, Williams RD: Management of Prostate Cancer. In Crawford ED, Das S (eds): Cancer of the Prostate. New York: Marcel Dekker, Inc., 1993.

35. See WA, Dreicer R, Cohen MB: Adult Tumors of the Ureter and Bladder. In Bahnson RR (ed): Management of Urologic Disorders. New York: Mosby Year Book, Ltd., 1994.

36. See WA: Tumor Markers in the Management of Testicular Carcinoma. In Schnorr D, Loening SA, Weisbach L (ed): Testis Cancer. Berlin:Blackwell Wissenschaft, 1994.

37. See WA: Cause, Effect, and Management of General Complications of Laparoscopy. In Fahlenkamp D (ed): Urologic Laparoscopy Berlin: Blackwell Wissenschaft, 1995

38. Zenni MK, See WA: Testicular mass, adult and pediatric. In Gomella LG, Dambro M (eds): 5 Minute Urology Consult. Baltimore: Williams and Wilkins.

39. Schrepferman, C, See WA: Vasomotor instability. In Gomella LG, Dambro M (eds): 5 Minute Urology Consult. Baltimore: Williams and Wilkins

40. See WA: Neoadjuvant hormonal therapy in prostate cancer. In Perry MC (ed): American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology, 1998.

41. Theodorescu D and See WA: Biology and molecular aspects of development and progression of bladder cancer. In Droller MJ (ed): Bladder Cancer: Current Diagnosis and Treatment. Totowa: Humana Press 2001

42. Denson M, Smither A, and See WA: Controversies in the management choices for the treatment of prostate cancer. In Abel P and Lalani N (ed): Prostate Cancer: Scientific and Clinical Aspects. Bridging the Gap. London: Imperial College Press Co. Ltd 2005

43. Guralnick M, O'Connor R, See WA: Assessment and Management of Irritative Voiding Symptoms: Urologic Issues for the Internist, Medical Clinics of North America, Jan 2011.

1. See WA, Gill WB, Bagley DM: Transitional tumor cell adherence to injured urothelium. Association for Academic Surgery Annual Meeting; 1982.

2. Lee VK, See WA, Hellstrom I, Hellstrom KE: An immunotherapeutic model for murine transitional cell carcinoma. Conference on Immunity to Cancer; September 1984.

3. See WA, Chou CK, Luk KA, Chapman WH: A model for microwave hyperthermia in bladder carcinoma in rats. American Urological Association Annual Meeting; May 1985.

4. See WA, Mack LA, Krieger JK: Ultrasonography in the management of complicated epididymitis. Western Section American Urological Association Meeting; July 1985.

5. See WA, Mack LA: Scrotal ultrasonography: A predictor of epididymitis requiring orchiectomy. American Urological Association Annual Meeting; May 1986.

6. See WA, Chapman WH: Tumor cell implantation following neodymium-YAG bladder injury: A comparison to electrocautery injury. Western Section American Urological Association Meeting; July 1986.

7. Soucie Muir TY, See WA, Chapman WH: An evaluation of the noninvasive portable ultrasound instrument for measuring bladder volumes. American Urological Association Allied Annual Meeting; July 1986

8. See WA, Richards T, Mack LA, Chapman WH, Wesbey GE: P-31 NMR spectroscopy as a predictor of testicular viability following ischemic injury. Society of Magnetic Resonance in Medical Annual Meeting; August 1986.

9. Haynor DR, Richards T, See WA, Wesbey GE: Perfluorocarbons for detection of tissue perfusion: Use of pulsed field gradients. Society of Magnetic Resonance in Medical Annual Meeting; August 1986.

10. See WA, Chapman PH: Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. Western Section American Urological Association Annual Meeting; February 1987.

11. See WA, Chapman PH: Clinical variables influencing transitional cell tumor implantation in an experimental model. Northwest Urological Society Annual Meeting; 1987.

12. See WA, Sislow JG, Ireton RC: Initial experience with the Indiana pouch at the University of Washington. Northwest Urological Society Annual Meeting; 1987.

13. Miller J, See WA: Auditory-visual hallucinations associated with trimethoprim-sulfamethoxazole therapy: A case report and review of the literature. Western Section American Urological Society Annual Meeting; 1988.

14. See WA, Chapman PH: Kinetics of tumor cell adherence to injured urothelium. American Urological Association Annual Meeting; June 1988.

15. Reed DC, Ireton RC, See WA: Continent urinary diversion: Seattle VAMC technique and initial experience with the "Indiana Pouch." Washington Chapter of the American College of Surgeons Annual Meeting; June 1988.

16. See WA, Peace DJ, Chapman WH: Continuous intravesical infusion, or intralesional IL2, with or without LAK cells, for the treatment of transitional cell bladder carcinoma. American Urological Association Annual Meeting; May 1989.

17. See WA, Williams RD: Mechanism by which intravesical heparin decreases particulate adherence to areas of urothelial injury: An alternative theory to the gag repletion hypothesis. American Urological Association Annual Meeting; May 1989.

18. See WA, Williams RD: Initiating mechanisms in bladder tumor recurrence resulting from tumor cell implantation. North Central Section American Urological Association Annual Meeting; September 1989.

19. See WA, Williams RD: Single dose preoperative systemic chemotherapy for the prevention of bladder tumor recurrence resulting from implantation. North Central Section American Urological Association Annual Meeting; September 1989.

20. See WA, Williams RD: Intravesical thrombolytic agents for bladder tumor recurrence prophylaxis: Preclinical evaluation of recombinant tissue plasminogen activator. American Urological Association Annual Meeting; 1990.

21. Rohlf DP, See WA, Williams RD: Molecular mechanisms mediating tumor cell attachment to sites of bladder injury. American Urological Association Annual Meeting; 1990.

22. See WA, Williams RD: The role of integrins in mediating transitional tumor cell adherence to extracellular matrix proteins at sites of urothelial injury. American Association for Cancer Research Annual Meeting; 1990.

23. See WA, Smith JL: Activated proteolytic enzymes in the urine of whole organ pancreas transplant patients with pancreatico-duodeno-cystostomys. International Transplantation Society Annual Meeting; 1990.

24. Smith JL, See WA, Corry RJ: Lower urinary tract complications in patients with duodeno-cystostomies for exocrine drainage of transplanted pancreas. International Transplantation Society Annual Meeting; 1990.

25. Fallon B, See WA: Superficial transitional cell carcinoma in women-recurrence patterns and factors involved. North Central Section American Urological Association Annual Meeting; October 1990.

26. Sargent E, See WA, Williams RD: Changes in urinary EGF levels associated with iatrogenic urothelial trauma. North Central Section American Urological Association Annual Meeting; October 1990.

27. See WA, Smith JL: Urinary levels of active trypsin in whole organ pancreas transplant patients with pancreatic-duodeno-cystostomies. North Central Section American Urological Association Annual Meeting; October 1990.

28. See WA, McDermott T, Xia Q, Williams RD: Regional drug delivery into the rat urinary bladder: A system for continuous infusion. North Central Section American Urological Association Annual Meeting; October 1990.

29. Winfield HN, See WA, Donovan JF, Loening SA, Williams RD: A new cancer staging technique: Laparoscopic pelvic node dissection. American Urological Association Annual Meeting; June 1991.

30. Cooper CS, See WA: The impact of iatrogenic urothelial trauma on urinary levels of transforming growth factor-alpha in an animal model. American Urological Association Annual Meeting; June 1991.

31. See WA, Cooper CS, Sargent ER: Urinary levels of transforming growth factor-A in response to surgical bladder injury. American Association for Cancer Research; May 1991.

32. See WA, Williams RD: Tumor associated plasminogen activator as a regulator of tumor cell adherence to sites of surgical trauma. American Association for Cancer Research; May 1991.

33. Winfield HN, See WA, Donovan JF, Loening SA, Williams RD: Laparoscopic urologic pelvic lymph node dissection (videotape). American Urological Association Annual Meeting; June 1991.

34. Winfield HN, See WA, Donovan JF, Loening SA, Williams RD: Laparoscopic pelvic lymph node dissection - A new staging technique for cancer of the prostate. 9th World Congress on Endourology and ESWL - 7th Annual Research Symposium on ESWL; June 1991.

35. See WA, Xia Q: Dimethyl-Sulfoxide (DMSO) Augments Regional Delivery of Chemotherapeutic Agents While Simultaneously Increasing Tumor-Drug Sensitivity. 77th Clinical Congress of the American College of Surgeons; October 1991

36. Winfield HN, See WA, Donovan JF, Loening SA, Williams RD: Laparoscopic pelvic lymph node dissection: A minimally invasive staging procedure. 22nd Congress of the SociÈtÈ Internationale D'Urologie; November 1991.

37. Crusinberry R, See WA: Purinergic autonomic transmission in experimentally-induced benign prostatic hypertrophy in rats. North Central Section American Urological Association Annual Meeting; November 1991.

38. Crusinberry R, See WA: Purinergic autonomic transmission in short-term diabetic rat bladders. North Central Section American Urological Association Annual Meeting; November 1991.

39. Winfield HN, See WA, Donovan JF, Loening SA, Williams RD: Laparoscopic pelvic lymph node dissection for cancer of the prostate. North Central Section American Urological Association Annual Meeting; November 1991.

40. Griebling TC, See WA: Potentiation of doxorubicin and thio tepa cytotoxicity against transitional cell carcinomas by dimethyl-sulfoxide. North Central Section American Urological Association Annual Meeting; November 1991.

41. See WA, Xia Q: Regional chemotherapy for bladder neoplasms using continuous intravesical infusion doxorubicin: Impact of Concomitant DMSO administration on drug absorption and anti-tumor activity. North Central Section American Urological Association Annual Meeting; November 1991.

42. Winfield HN, Donovan JF, See WA, Loening SA, Williams RD: Laparoscopic surgery in complicated patients. The use of the Hasson cannula. The Society for Minimally Invasive Surgery; November 1991.

43. See WA, Cooper CS, Crist SA: Urine from iatrogenically traumatized bladders promotes transitional carcinoma cell growth in a manner consistent with a growth factor dependent mechanism. Society for Basic Urologic Research Fall Symposium; November 1991.

44. Hoxie LD, See WA: Chest staging in testes cancer patients with negative abdominal CT scans: is chest CT necessary? American Urological Association Annual Meeting; May 1992.

45. See WA, Fisher RL, Winfield HN, Donovan JF: Laparoscopic surgical training: Effectiveness and impact on urologic surgical practice patterns. American Urological Association Annual Meeting; May 1992.

46. Jewett KA, See WA, Sargent ER, Crist SA: Urinary epidermal growth factor levels following various iatrogenic lower urinary tract manipulation. American Urological Association Annual Meeting; May 1992.

47. Winfield HN, See WA, Donovan JF, Loening SA, Godet A, Farange Y, Williams RD: Comparative effectiveness and safety of laparoscopic vs. open pelvic lymph node dissection for cancer of the prostate. American Urological Association Annual Meeting; May 1992

48. Farange Y, Winfield HN, See WA, Godet AS: Open laparoscopy and adhesiolysis combined with pelvic lymph node dissection (videotape). American Urological Association Annual Meeting; May 1992.

49. Betz SA, See WA, Cohen MB: The cytologic appearance of granulomatous inflammation following BCG therapy for bladder cancer. American Society of Cytology Annual Meeting; May 1992.

50. See WA, Cohen MB, Winfield HN: Inverted V peritoneotomy significantly improves nodal yield in laparoscopic pelvic lymphadenectomy. North Central Section American Urological Association Annual Meeting; October 1992.

51. See WA, Hoxie LD: Interval change analysis of Alpha-feto protein half-life improves predictive value of serum markers for nodal disease status relative to conventional half-life measurements. North Central Section American Urological Association Annual Meeting; October 1992.

52. Winfield HN, See WA, Donovan JF, Loening SA, Williams RD: Laparoscopic pelvic lymph node dissection for cancer of prostate: Predictors of node positivity. American Urological Association Annual Meeting; May 1993.

53. Griebling TL, Winfield HN, Donovan JF, See WA, Loening SA, Williams RD: Immediate versus delayed radical prostatectomy after laparoscopic pelvic lymph node dissection for prostate cancer. American Urological Association Annual Meeting; May, 1993.

54. See WA, Cohen MB, Winfield HN: Inverted V peritoneotomy significantly improves nodal yield in laparoscopic pelvic lymphadenectomy. American Urological Association Annual Meeting; May, 1993.

55. See WA, Yong X, Crist S, Hedican S, Sabharwal S: Intertumor and intratumor variation in bladder cancer plasminogen activator activity: responsible factors and correlation with invasion into and adherence on extracellular matrix proteins. Society for Basic Urologic Research Annual Meeting; May 1993.

56. See WA, Cooper CS, Fisher RJ: Early and late predictors of laparoscopic complication rates following a formal training course in laparoscopic surgery. North Central Section American Urological Association Annual Meeting; October 1993.

57. Fuller JR, Fisher RA, See WA, Lubaroff DM, Riggs CE: Effects of suramin on cell cycle kinetics of rat and human transitional cell carcinoma in vitro. North Central Section American Urological Association Annual Meeting; October 1993.

58. Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham SD, Grossman HB, See WA, et al. Bropirimine immunotherapy of bladder CIS: Positive phase II trial results of an oral interferon inducer. American Urological Association Annual Meeting; May 1994

59. Terrell B, Cheville J, See WA, Cohen MB: Histopathologic features as predictors of survival in patients with transitional cell carcinoma (TCC) of the renal pelvis. American Urological Association Annual Meeting; May 1994

60. Cooper CS, Fisher RJ, See WA: Laparoscopic practice patterns and complication rates in the year following formal training. American Urological Association Annual Meeting; May 1994

61. Crist S, Xu Y, Hedican S, See WA: Variance in cellular plasminogen activator activity in clonal cell populations derived from a transitional carcinoma cell line. American Urological Association Annual Meeting; May 1994

62. See WA, Forest PK, Dreicer R: A pilot trial of continuous infusion, intraluminal doxorubicin, with or without DMSO, for the treatment of regionally advanced bladder cancer. Western Section American Urological Association Annual Meeting; August 1994.

63. See WA, Cooper CS, Forest PK: A phase I/II trial of perioperative, systemic, single dose cyclophosphamide for the prevention of superficial bladder tumor recurrence. Western Section American Urological Association Annual Meeting; August 1994

64. Terrell RB, Cheville JC, See WA, Cohen MB: p53 nuclear protein overexpression as a predictor of survival and tumor recurrence in transitional cell carcinoma (TCC) of the renal pelvis. North Central Section American Urological Association Annual Meeting; October 1994.

65. Xu Y, Gee K, Rochlan O, Severson CD, Cohen MB, See WA: Soluble urinary factors elicited in response to transurethral tumor resection regulate fibronectin (FN) expression in bladder tumor cell lines. American Urological Association Annual Meeting; April 1995.

66. Xu Y, See WA: The differential response of cellular proliferation and plasminogen activator regulation to transforming growth factor-b1 in transitional carcinoma cell lines. American Urological Association Annual Meeting; April 1995

67. Xu Y, Stork B, Sabarwhal S, Gross T, Severson CD, See WA: Urinary plasminogen activator receptor expression: Correlation with the in vitro, plasminogen-dependent invasive human transitional carcinoma cell lines. American Urological Association Annual Meeting; April 1995

68. Xu Y, Stork B, Sabarwhal S, Gross T, Severson CD, See WA: Transforming growth factor-beta-1 (TGF-beta-1) and the plasminogen activator (PA) system in the biology of transitional carcinoma cell (TCC) lines. American Urological Association Annual Meeting; April 1995

69. Glascock, JM, Winfield HN, Donovan JF, See WA, Loening SA , Williams RD: Staging adenocarcinoma of the prostate: a survey of the first 200 laparoscopic pelvic lymphadenectomies (LPLND). American Urological Association Annual Meeting; April 1995.

70. Narepalem N, Winfield HN, Donovan JF, See WA, Loening SA: Laparoscopic pelvic lymph node dissection (LPLND) improves clinical staging in patients receiving definitive radiotherapy for cancer of the prostate (CAP). American Urological Association Annual Meeting; April 1995.

71. Griebling TL, Ozkutlu D, See WA, Cohen MB: Prognostic implications of extracapsular extension of lymph node metastases in human prostate cancer. North Central Section American Urological Association Annual Meeting; September 1995

72. Loening SA, Dreicer R, Forest PK, See WA: Brachytherapy versus brachytherapy and continuous infusion 5-fluorouracil for the treatment of locally advanced, node negative prostate cancer. North Central Section American Urological Association Annual Meeting; September, 1995.

73. Dreicer R, Gustin D, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. American Urological Association Annual Meeting; May 1996.

74. Cohen MB, Ozkutla D, See WA, Griebling TL: Prognostic implications of lymph node extracapsular extension in regionally metastatic prostate cancer. American Urological Association Annual Meeting; May 1996.

75. Ladehoff D, Xu Y, See WA: Induction of fibronectin expression in transitional carcinoma cell lines by post-TURBT urine: time course and TGFb1 dependence. American Urological Association Annual Meeting; May 1996.

76. Callaghan EJ, See WA, Dreicer R, Cohen MB: Cytologic changes associated with intravesical adriamycin therapy for invasive transitional cell carcinoma (TCC) of the bladder. United States and Canadian Academy of Pathology, 1996.

77. Fourcade RO, McLeod D, See WA, Iversoen P, Wirthe M, Cosaert J, Smith KG, Kolvenbag G, Millson D, Webster A: Can hormonal treatment be beneficial for non-metastatic cancer patients? Initiation of a world-wide study. International Conference on Prostate Cancer. Monte Carlo, June 1996.

78. See WA: Late retroperitoneal relapse of germ cell tumors is associated with an increased risk of nephrectomy at the time of RPLND. North Central Section American Urological Association Annual Meeting; October 1996.

79. See WA: Continuous antegrade infusion doxorubicin (CAID) for transitional cell carcinoma of the upper urinary tract. North Central Section American Urological Association Annual Meeting; October 1996.

80. See WA, Dreicer R: Radical TURBT and continuous infusion intraluminal gallium (CIIG) as bladder-preserving treatment for muscle invasive bladder cancer. North Central Section American Urological Association Annual Meeting; October 1996.

81. Dreicer R, Galbraith SS, Davis CS, See WA: Surgical resection of metastatic renal cell carcinoma: University of Iowa experience. American Urological Association Annual Meeting; April 1997

82. Zhang G-J, Xu Y, Ladehoff DC, See WA: IL-6 cDNA transfection of a human TCC cell line increases expression and functional activity of fibronectin receptors in vitro. American Urological Association Annual Meeting; April 1997

83. Cohen MB, Ozkutlu D, See WA, Griebling TL: Prognostic implications of lymph node extracapsular extension in regionally metastatic prostate cancer. American Urological Association Annual Meeting; April 1997.

84. Burns JA, Kreder KJ, Lubaroff DM, See WA: Alterations in constituent urinary proteins in response to bladder outlet obstruction. American Urological Association Annual Meeting; April 1997.

85. Mulholland TL, See WA. Pledgeted sutures for parenchymal compression facilitate partial nephrectomy. North Central Section American Urological Association Annual Meeting; September, 1997

86. Porter MF, Ahagohtu CA, Loening SA, See WA. Disease free and overall survival following cryosurgical monotherapy for clinically organ confined prostate cancer. North Central Section American Urological Association Annual Meeting; September, 1997

87. Kusek JW, O'Berry K, Burrows PK, See WA, Fearing M, Kreder K for the MTOPS Research Group. Use of mass mail to recruit older men into a clinical trial for medical treatment of benign prostatic hyperplasia (BPH): the medical therapy of prostatic symptoms (MTOPS) trial. Society for Clinical Trials Annual Meeting; May 1998.

88. Burns JA, Crist SA, Kreder KJ, Cohen MB, See WA. Temporal and spatial localization of lower urinary tract basic FGF circa bladder outflow obstruction. American Urological Association Annual Meeting; May 1998.

89. Colegrove PM, Winfield HN, Donovan JF, See WA. Urological laparoscopic practice patterns 5 years after formal training. American Urological Association Annual Meeting; May 1998.

90. Zhang G-J, Ladehoff DC, Xu Y, See WA. Expression of FN and PAI-1 is unregulated by autocrine TGFb-1 in a human transitional carcinoma cell (TCC) line. American Urological Association Annual Meeting; May 1998

91. Zenni MK, Griebling TL, Kreder KJ, Titler MG, See WA, Williams RD. Impact of preoperative comorbidity on complications and costs in patients undergoing radical cystectomy and orthotopic urinary diversion. American Urological Association Annual Meeting; May 1998.

92. Binanchi GD, Cerhan JR, Parker AS, Putnam SD, Cantor KP, See WA, Lynch CF. Tea consumption and risk of kidney cancer: A population-based case-control study. 31st Annual Meeting of the Society for Epidemiologic Research. Chicago, IL; June, 1998

93. Austin JC, Siemens DR, See WA, Ratliff TL, Tartaglia J. Effects of volume and pressure during intravesical instillation of ALVAC-luciferase on levels of gene expression and systemic distribution. American Urological Association Annual Meeting, May 1999.

94. Griebling TL, Sueppel CA, Kreder KJ, See WA. Comparison of pre-and Post-operative biofeedback training for men undergoing radical prostatectomy. American Urological Association, North Central Section, Annual Meeting, September 1999.

95. McKerrow AK, Crist SA, Zhang G-J, Ladehoff DC, Zhao W, Ratliff TL,See WA. BCG adherence correlates with fibronectin avidity across human bladder cancer cell lines. American Urological Association, North Central Section Annual Meeting, September 1999.

96. Siemens DR, Iwasawa T, Austin JC, Williams RD, See WA, Hedican SP, Tartaglia J, Cohen MB, Ratliff TL. Biomarker distribution after injection In the canine prostate: Implications for gene therapy. 3rd World Congress on Urological Research. Paris, France; September, 1999.

97. Fourcade RO; Wirth M; See WA, McLeod DG; Iversen P: The "Bicalutamide EPC" Program: demographic results for 8113 randomized patients. Progres en Urologie, 1999, 9(5) Suppl 1 pp P21 Abs P21. 93rd Congres Francais D'Urologie Programme et Resumes, Paris, 17-21 Nov 1999.

98. Dreicer R, See WA, Elson P and Klein E. Phase II trial of GM-CSF in patients with advanced prostate cancer. American Society of Clinical Oncologists, 2000

99. See WA, Kreder K, Greibling T: Intussucepted vesico-urethral Anastomosis facilitates early return of continence following radical retropubic prostatectomy, American Urologic Association, Annual Meeting, May 2000.

100. Siemans DR, Tartaglia J, Iwasawa T, Austin JC, William RD, See WA, Hedican SP, Cohen MB, Ratliff T: Delivery of viaral vectors in a gelatin matrix enhances gene expression in the canine prostate. American Urologic Association Annual Meeting, May 2000

101. See WA: Recovery of Urinary Continence Following Radical Retropubic Prostatectomy (RRP): Longitudinal Assessment by Quantitative PAD Testing. American Urologic Association, North Central Annual Meeting, October 2000

102. See WA: Quantitative Measurement of Post-Radical Prostatectomy (RRP)Incontinence: Correlation with Patient Completed Survey Instruments. American Urologic Association, North Central Annual Meeting, October 2000

103. Wirth M, See WA, McLeod D, Iverson P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere K, Vaage S, Tammela T, Lukkarinen O, Persson B. Bicalutamide ('Casodex' 150mg) as immediate or adjuvant herapy in 8113 men with localized or locally advanced prostate cancer. San Francisco, CA ASCO May 2001

104. McLeod D, See W, Iversen P, Wirth M, Beckman R, Carroll K. Tolerability of bicalutamide ('Casodex' 150mg) as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. Podium presentation. American Urological Association Annual Meeting, June 2001.

105. Zhang GJ, Iwamoto Y, See WA, Crist SA. Expression of Interleukin-6 (IL-6) by Human Transitional Carcinoma Cell (TCC) Lines in Response to Bacille Calmette Guerin (BCG) Occurs via an Immediate-Early Signaling Pathway Requiring AP-1 and NFB; American Urological Association Annual Meeting, Anaheim, CA, June 2001.

106. Neeb AD, Langenstroer P, See WA. Quantitative Measurement of Post-Radical Prostatectomy (RRP) Incontinence: Correlation with Patient Completed Survey Instruments; American Urological Association Annual Meeting, Anaheim, CA, June 2001.

107. Chen FH, Zhang GJ, Iwamoto Y, See WA. Aspirin Inhibits Bacille Calmette Guerin (BCG) Induced Expression of Interleukin-6 (IL-6) in Human Transitional Carcinoma Cell (TCC) Lines; American Urological Association Annual Meeting, Anaheim, CA, June 2001.

108. McLeod D, See W, Iversen P, Wirth M, Beckman R, Carroll K. Tolerability of bicalutamide ('Casodex' 150mg) as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. American Society of Clinical Oncologists Meeting, 2001.

109. Tyrrell C, Payne H, Wirth M, Iversen P, See W, McLeod D, Persson B-E, Carroll K. Bicalutamide ('Casodex') 150mg as adjuvant to radiotherapy in localized or locally advanced prostate cancer; European College of Clinical Oncologists Podium Presentation, 2001.

110. Tyrrell C, Payne H, Wirth M, Iversen P, See W, McLeod D, Persson B-E, Carroll K. Bicalutamide ('Casodex') 150mg as adjuvant to radiotherapy in localized or locally advanced prostate cancer; ASTRO podium presentation, 2001.

111. McLeod D, See W, Wirth M, Iversen P, Carroll K, Persson B-E. Is prostate-specific antigen (PSA) doubling a valid method of assessing disease progression. American Society of Clinical Oncologists, 2001.

112. Wirth M, See W, McLeod D, Iversen P, Perrsson E-E, Carroll K. Bicalutamide ('Casodex') 150 mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. American Society of Clinical Oncologists, 2001.

113. See WA, Wirth M, McLeod D, Iverson O, Persson B, Carroll K. Immediate Treatment with bicalutamide reduces the risk of disease progression in early non-metastatic prostate cancer irrespective of primary therapy. Birmingham, UK European Association of Urologists. February 2002

114. Iversen P, Wirth M, See W, McLeod D, Morris T, Carroll K on behalf of the 'Casodex' Early Prostate Cancer Trialists's Group. Is the efficacy of hormonal therapy affected by lymph node status? New data from the bicalutamide EPC programme. Birmingham, UK European Association of Urologists podium presentation. February 2002.

115. Kajdacsy-Balla A, See W, Guo S-W. Methods currently used for designing tissue microarrays to validate prognostic markers. An analysis of the literature. 2nd International NCI-EORTC Meeting on Cancer Diagnostics. From Discovery to Clinical Practice. Bethesda, MD. April 2002.

116. Wilson JA, Langenstroer P, See WA. Digital Rectal Exam: Positive Predictive Value for Detecting and Localizing Clinical Prostate Cancer. Wisconsin Urological Society Annual Meeting, Kohler, Wisconsin, May 2002.

117. Evans JM, See WA. Prostate Volume and its Relation to Blood Loss and Continence in Radical Retropubic Prostatectomy. Wisconsin Urological Society Annual Meeting, Kohler, Wisconsin, May 2002.

118. Chen F, Zhang G, Iwamoto Y, See W. 51 Integrin Cross-Linking Mimics BCG Induced Signal Transduction in a Human Transitional Carcinoma Cell Line. American Urological Association Annual Meeting, Orlando, FL, May 2002.

119. Zhang G, See WA. Microarray Analysis of the Effect of Post-TURBT Urine (PTU) on TGF1 Dependent Gene Expression in Transitional Cell Carcinoma (TCC). American Urological Association Annual Meeting, Orlando, FL, May 2002.

120. Zhang G, Chen F, Crist SA, McKerrow A, Iwamoto, Y, Ratliff, TL, See WA. Autocrine Overexpression of Fibronectin by Human Transitional Carcinoma Cells (TCC) Impairs BCG Adherence and Signaling. American Urological Association Annual Meeting, Orlando, FL, May 2002.

121. McLeod D, See WA, Wirth M, Iverson P, Carroll K, Persson B. Prostate-specific antigen doubling is a valid method of assessing disease progression. American Urological Association Annual Meeting, Orlando, FL May 2002

122. Wirth M, McLeod D, Iverson P, See WA , Morris T, Carroll K. Efficacy of bicalutamide in early non-metastatic prostate cancer by initial disease stage and grade. American Urological Association Annual Meeting, Orlando, FL, May 2002

123. Iverson P, Wirth M, See WA, McLeod D, Morris T, Carroll K. Is the efficacy of hormonal therapy affected by lymph node status? New data from the bicalutamide EPC program. American Urological Association Annual Meeting, Orlando, FL, May 2002

124. Balla A, See WA, Guo S. Methods Currently Used for Designing Tissue Microarrays to Validate Prognostic Markers. An Analysis of the Literature. International Journal of Biological Markers 2002;17-S2: S37-S38. Podium presentation at the Second NCI-EORTC International Workshop on the Development of New Diagnostic Tools for Cancer, From Discovery to Clinical Practice: Diagnostics Innovation, Implementation and Evaluation. June 2002, Washington DC, USA.

125. Smither A, See WA. The Effect of Pubo-Prostatic Ligament (PPL) Preservation on the Early Recovery of Continence Following Radical Retropubic Prostatectomy (RRP). 76th Annual Meeting of the North Central Section, American Urological Association, Chicago, IL, September 2002.

126. Wilson J, See WA. Prostate Volume at the Time of Radical Retropubic Prostatectomy (RRP Correlates with Intraoperative Blood Loss and Postoperative Continence Recovery. 76th Annual Meeting of the North Central Section, American Urological Association, Chicago, IL, September 2002.

127. Iversen P, Wirth M, See W, McLeod D, Morris T, Carroll K. Is the efficacy of hormonal therapy affected by lymph node status? New data from the bicalutamide EPC program. 76th Annual Meeting of the North Central Section, American Urological Association, Chicago, IL, September 2002.

128. Wirth M, McLeod D, Iversen P, See W, Morris T, Carroll K. Efficacy of bicalutamide in early, non-metastatic prostate cancer by initial disease stage and grade. 76th Annual Meeting of the North Central Section, American Urological Association, Chicago, IL, September 2002

129. See WA. Adjuvant Hormonal Therapy in Early Prostate Cancer: Results of the EPC Program. Japanese Urological Association Annual Meeting, Chiba, Japan, September 2002.

130. McLeod D, See WA, Wirth M, Iverson P, Carroll K, Persson B. Prostatic-specific antigen doubling is a valid method of assessing disease progression Stockholm, Sweden, September 2002

131. Wirth M, McLeod D, Iversen P, See W, Morris T, Carroll K. Efficacy of bicalutamide in early, non-metastatic prostate cancer by initial disease stage and grade. J Urol 167(4), 2002.

132. Payne H, See WA, McLeod DG, Wirth MP, Iverson P, Garside L. New Analysis Indicates that Adjuvant Bicalutamide ('Casodex') 150 MG Significantly Improves Progression-Free Survival Following Radiotherapy for Early Prostate Cancer. The European Urological Association Meeting, 2003

133. See WA, Wirth MP, McLeod DG, Iversen P. International Differences in Prostate Cancer Treatment Outcomes Correlate with Pretreatment PSA Level and Clinical Stage: Results of an Ongoing, Prospective, International Trial Programme. The European Urological Association Meeting, 2003.

134. Fourcade R-O, Klimberg I, See WA, Wirth MP, McLeod DG, Iversen P, Garside L. Bicalutamide ('Casodex') 150 MG as Adjuvant to Radical Prostatectomy Significantly Increases Progression-Free Survival in Early Prostate Cancer: Evidence From a New Analysis. The European Urological Association Meeting, Madrid, Spain, March 2003.

135. Wallace WMA, Iversen P, Wirth MP, McLeod DG, See WA, Garside L. New Analysis Shows that Immediate Treatment with Bicalutamide ('Casodex') 150 mg/Day Delays Disease Progression in Patients with Early Prostate Cancer Who Would Otherwise Opt for Watchful Waiting. The European Urological Association Meeting, 2003.

136. Wirth MP, McLeod DG, Iversen P, See WA, Carroll K, Morris T. Update from the Bicalutamide ('Casodex') Early Prostate Cancer Programme. The European Urological Association Meeting, 2003.

137. See WA, Wirth M, McLeod D, Iverson P, Garside L, Morris T. Benefits of Adjuvant Bicalutamide (Casodex) 150 mg in High-Risk Patients After Radical Prostatectomy or Radiotherapy for Early Prostate Cancer. American Society for Clinical Oncology Annual Meeting, Chicago, IL, May 2003

138. Murphy MJ, See WA. Bladder Neck Contracture Following Radical Retropubic Prostatectomy with Employment of Intussuscepted Urethral-Bladder Anastomosis. Wisconsin Urological Society Annual Meeting, Milwaukee, WI, May 2003.

139. Wilson JA, Evans JM, See WA. Prostate Volume at the Time of Radical Retropubic Prostatectomy Correlates with Intraoperative Blood Loss and Postoperative Continence Recovery. Wisconsin Urological Society Annual Meeting, Milwaukee, WI, May 2003.

140. Smither AR, See WA, Rewcastle J, Donnell RF. Cryotherapy for Prostate Cancer Recurrence Following Definitive Radiation Therapy: Initial Results from the Medical College of Wisconsin. Wisconsin Urological Society Annual Meeting, Milwaukee, WI, May 2003.

141. Wirth M, McLeod D, Iversen P, See WA, Morris T, Carroll K. Efficacy of Bicalutamide in Early, Non-Metastatic Prostate Cancer by Initial Disease Stage and Grade. American Urological Association Annual Meeting, Chicago, IL, April 2003.

142. Klimberg I, See WA, Wirth MP, McLeod DG, Iversen P, Soloway M, Garside L. New Analysis Shows that Bicalutamide 150 mg as Adjuvant to Radical Prostatectomy Significantly Increases Progression-free Survival in Early Prostate Cancer. American Urological Association Annual Meeting, Chicago, IL, April 2003.

143. See WA, Wirth M, McLeod D, Iverson P. International differences in prostate cancer treatment outcomes correlate with clinical stage and pretreatment prostate-specific antigen level: results of an ongoing prospective, international trail program. American Urological Association Annual Meeting, Chicago, IL, April 2003.

144. Chen F, Zhang G, Langenstroer P, Iwamoto Y, See WA. Androgen Dependent Regulation of BCG Induced Interleukin-6 (IL-6) Expression in Human Transitional Carcinoma Cell (TCC) Lines. American Urological Association Annual Meeting, Chicago, IL, April 2003.

145. Tyrrell C, See WA, McLeod D, Wirth MP, Iversen P, Garside L. Adjuvant Bicalutamide 150 mg Significantly Improves Progression-Free Survival Following Radiotherapy for Early Prostate Cancer. American Urological Association Annual Meeting, Chicago, IL, April 2003.

146. McLeod D, See WA, Iverson P, Wirth M, Garside I, Morris T. Immediate bicalutamide 150 mg therapy significantly reduces the risk of disease progression in patients with localized prostate cancer who would otherwise be candidates for watchful waiting. ASCO, Chicago, Il May 2003

147. See WA, Wirth M, McLeod D, Iverson P, Garside L, Morris T. Benefits of adjuvant bicalutamide 150 mg in high-risk patients after radical prostatectomy or radiotherapy for early prostate cancer. ASCO, Chicago, Il May 2003

148. Wirth MP, Iversen P, McLeod DG, See WA, Armstrong J, Morris T. Response to Second-Line Hormonal therapy Following Progression on Bicalutamide 150 mg Monotherapy. European Association of Urologists. Vienna, Austria. March 2004

149. McLeod, D, Iversen P, See WA, Wirth M, Carroll K, Morris C, Morris T. Bicalutamide ('Casodex') 150 mg as Adjuvant to Radiotherapy Significantly Improves Progression-Free Survival in Early, Non-Metastatic Prostate Cancer: Results from the Bicalutamide Early Prostate Cancer Programme After a Median 5.4 Years' Follow-Up. 2004 European Urology Association Meeting, Vienna, Austria. March 2004

150. Iversen P, McLeod D, See WA, Wirth M, Morris T, Morris C, Carroll K. Bicalutamide ('Casodex') 150 mg in Addition to Watchful Waiting in Patients with Early, Non-Metastatic Prostate Cancer: Updated Analysis at a Median 5.4 Year's Follow-Up. 2004 European Urology Association Meeting, Vienna, Austria. March 2004

151. Wirth M, Iversen P, McLeod D, See WA, Morris C, Morris T, Carroll K. Bicalutamide ('Casodex') 150 mg as Adjuvant to Radical Prostatectomy Significantly Increases Progression-Free Survival in Patients with Early Non-Metastatic Prostate Cancer: Analysis at a Median Follow-Up of 5.4 Years. 2004 European Urology Association Meeting, Vienna, Austria. March 2004

152. Zhang G, Cao Y, Chen F, See WA. BCG Induces P21 Expression in Human Transitional Carcinoma Cell Lines Via an Immediate-Early, P53 Independent, Pathway. American Urological Association Annual Meeting, San Francisco, CA, May 2004.

153. Chen F, Zhang G, See WA. Androgen Dependent Regulation of BCG Induced Cell Growth Arrest in Human Transitional Carcinoma Cell Lines. American Urological Association Annual Meeting, San Francisco, CA, May 2004.

154. Murphy MJ, See WA. Bladder Neck Contracture Rates Following RRP Using an Intussuscepted Vesicourethral Anastomosis. American Urological Association Annual Meeting, San Francisco, CA, May 2004.

155. See WA, Iversen P, McLeod DG, Wirth MP, Carroll K, Morris T, Morris C. Bicalutamide 150 mg in Addition to Standard Care Significantly Improves Prostate Specific Antigen Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer: Median 5.4 Year's Follow-Up. American Urological Association Annual Meeting, San Francisco, CA, May 2004.

156. See WA, Iversen P, McLeod DG, Wirth M, Morris T, Carroll K. Bicalutamide 150 mg Alone or as Adjuvant to Standard Care Significantly Improves Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer (median 5.4 years' follow-up). American Urological Association Annual Meeting, San Francisco, CA, May 2004.

157. Iverson P, McLeod D, See, WA, Wirth M, Morris T, Carroll K. Bicalutamide 150 mg for early non-metastatic prostate cancer in patients who would otherwise undergo watchful waiting; latest results at a median 5.4 years' follow-up. American Urological Association Annual Meeting, San Francisco, CA, May 2004.

158. See WA, McLeod DG, Wirth MP, Iversen P, Morris T, Armstrong J. Adding Bicalutamide 150 mg to Standard Care Provides Clinical Benefit to Men with Locally Advanced Prostate Cancer: Findings from the Early Prostate Cancer Program at 5.4 Years' Median Follow-up. 2005 Multidisciplinary Prostate Cancer: Current Status and Future Directions for Prevention and Management, Orlando, FL, February 2005.

159. McLeod DG, See, WA, Klimberg I, Gleason D, Chodak GW, Morris T, Armstrong J. The Bicalutamide Early Prostate Cancer Program: findings of the North American Trial as Median 5.7 years' follow-up. American Urological Association Annual Meeting, San Antonia, TX, May, 2005

160. Zhang GJ, Cao Y, Chen FH, Iwamoto Y, See WA. Cytokines, Vitamins, and Small Modulate the Direct Antitumor effect of BCG and Alter P21 Transactivation. American Urological Association Annual Meeting, San Antonio, TX, May, 2005

161. Chen FH, Zhang GJ, Cao Y, Iwamoto Y, See WA. BCG Induced Gene Transactivation Inhibits Apoptosis in Human Urothelial Carcinoma Cell Lines in Response to Cytotoxic Agents. American Urological Association Annual Meeting, San Antonio, TX, May, 2005

162. Han R, Lu B, Tang Y, Wu c, Yao Z, Zhang GJ, See WA. The Gene Therapy of Bladder Cancer by Using Recombinant Adeno-Associated Virus Encoding Human Endostatin. American Urological Association Annual Meeting, San Antonio, TX, May, 2005

163. Chodak GW, Iverson P, McLeod DG, See WA, Wirth MP, Morris C, Armstrong J. Prostate-Specific Antigen levels as a Predictor of Prostate Bone Scans during follow-up after Standard Care for Prostate Cancer: Data from the Bicalutamide early Prostate Cancer Program. American Urological Association Annual Meeting, San Antonio, TX, May, 2005

164. See WA, McLeod D, Wirth M, Iverson P, Morris T, Armstrong J.Bicalutamide 150mg in addition to standard care delays progression to bone metastasis in locally advanced patients; Post-hoc analysis from the second analysis of the Early Prostate Cancer program. ASTO. Denver, CO October 2005

165. See WA, Langenstroer P. Using a Blueprint Process to Monitor Residency Program Compliance with Phase 3 of the ACGME Outcome Project. Marvin R Dunn poster session at ACGME Annual Education Conference, Kissimmee, Fl. March, 2006

166. Chodak GW, Iversen P, McLeod DG, See WA, Wirth MP, Morris C, Armstrong J. Prostate-specific Antigen Levels as a Predictor of Positive Bone Scans During Follow-up After Standard Care for Prostate Cancer: Data from the Bicalutamide Early Prostate Cancer Program. 2005 American Urological Association Annual Meeting

167. See, WA. Adding bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Prostate Cancer Symposium, San Francisco, CA. 2006

168. Posey ZQ, Weigelt JA, See WA. Grade IV Renal Parynchemal injury in patients following blunt trauma: Impact of ureteral stenting on outcome. AUA, Atlanta, GA, May 21, 2006

169. Chen F, Zhange G, Cao Y, Iwamoto Y, See, WA. Androgens and Interleukin-6 inhibit the direct anti-tumor effect of BCG in an additive manner. AUA, Atlanta, GA, May 22, 2006

170. Zhang G, Chen F, Cao Y, See, WA. Inducible P21 expression reproduces the direct anti-tumor effects of BCG on human Urothelial Carcinoma Cells AUA, Atlanta, GA, May 24, 2006

171. McLeod DG, Klimberg I, Gleason D, Chodak G, Morris T, Armstrong J, See, WA. The Bicalutamide early prostate cancer program: Findings of the North American trial at 7.7 years' median follow-up. AUA, Atlanta, GA, May 24, 2006

172. Mulligan M, Walters J, Schmeling GJ, Langenstroer P, See WA, Carrera GF, Daley B, Simpson D,. Improving GME through partnerships with graduate schools of education. Poster accepted for presentation at the Central Group for Educational Affairs, Association of American Medical Colleges Spring Conference 2007, Indianapolis, IN, March 22, 2007

173. Chen F, Zhang, G, Payne, R, See WA. Pre-treatment of Human Urothelial Cells with BCG Inhibits the Anti-Tumor Effect of Mitomycin C. Wisconsin Urological Society Abstract, Madison, WI, April, 2007

174. Zhang G, Chen F, Cao Y, See, WA CEBP Mediated Gene Transactivation and Increased RNA Stability are Responsible to Increased p21 Protein Levels in Urothelial Carcinoma Cells in Response to BCG. 2008 American Urological Association Annual Meeting. Orlando, FL

175. See, WA, Zhang G, Chen F, Kressin M, Langenstroer P. BCG Induces Necrotic Cell Death in Urothelial Carcinoma Cells Associated with the Release of the Chemokine HMGB1. 2008 American Urological Association Annual Meeting. Orlando, FL

176. Sudakoff G S, Dunn D P, Guralnick M L, Hellman R S, Eastwood D, See W A. Multidetector Computerized Tomography Urography as the Primary Imaging Modality for Detecting Urinary Tract Neoplasms in Patients with Asymptomatic Hematuria. Journal of Urology, Vol 179, 862-867, March, 2008

177. Guise A, Chen F, See WA. Estrodiol and gene expression in BCG treated bladder cancer. WUS, Kohler, WI March, 2008

178. Payne R, Guralnick M, Langenstroer P, See WA, Sudakoff GS, O'Connor RC. Smoking is not an independent risk factor in the development of ureteroenteric strictures following urinary diversion. WUS, Kohler, WI March, 2008

179. Garg T, See WA. Bladder neck contractor following RRP utilizing an intussuscepted vesico-urethral Anastomosis: incidence with long-term follow up. WUS, Kohler, WI March, 2008

180. O'Connor RC, Guralnick ML, Langenstroer P, See WA, Sandlow JI, Begun FP: Senior medical student opinions regarding the ideal urology interview day. 82nd Annual American Urological Association Meeting, North Center Section, Chicago, IL September, 2008

181. Schwartz IW, Garg T, Langenstroer P, Guralnick ML, See WA, O'Connor RC: Immediate total parental nutrition following Cystectomy and urinary diversion does not provide significant recovery benefit. 82nd Annual American Urological Association Meeting, North Center Section, Chicago, IL September, 2008

182. Garg T, See WA: Bladder Neck Contracture following Radical Regtropubic Prostatectomy Utilizing an Intussuscepted Vesico-Urethral Anastomosis: Incidence with Long-term Follow Up. North Center Section, Chicago, IL September, 2008

183. Garg T, Zhang G, Chen F Cao Y, See WA: Effect of Atorvastatin on Proliferation of Bladder Cancer Cells treated with Bacillus Calmette-Guerin (BCG), North Center Section, Chicago, IL September, 2008

184. Neff D, See WA: Comparison of RRP results in Patients with Prior Laparoscopic Herniorrhaphy Using Non-Absorbable Mesh (LMH) vs. a Control without Prior LMH Repairs. Annual Wisconsin Urological Society Meeting, Milwaukee, WI April, 2009

185. Garg T, Guralnick ML, Langenstroer P, See, WA, Hieb R, Rilling W, O'Connor RC: Resonance Metallic Ureteral Stents Do Not Successfully Treat Ureteroenteric Strictures in Patients with Ileal Conduits. . Annual Wisconsin Urological Society Meeting, Milwaukee, WI April, 2009

186. Rasmussen NR, See WA: High Molecular Group Box Protein 1 (HMGB1) Increases the Direct Cytotoxic Effect of BCG on Human Urothelial Carcinoma Cell. Annual Wisconsin Urological Society Meeting, Milwaukee, WI April, 2009

187. Neff D, See WA: Comparison of RRP results in Patients with Prior Laparoscopic Herniorrhaphy Using Non-Absorbable Mesh (LMH) vs. a Control without Prior LMH Repairs. Journal of Urology, Vol 181 (4) April, 2009

188. Garg T, Guralnick ML, Langenstroer P, See, WA, Hieb R, Rilling W, O'Connor RC: Resonance Metallic Ureteral Stents Do Not Successfully Treat Ureteroenteric Strictures in Patients with Ileal Conduits. Journal of Urology, Vol 181 (4) April, 2009

189. Rasmussen NR, See WA: High Molecular Group Box Protein 1 (HMGB1) Increases the Direct Cytotoxic Effect of BCG on Human Urothelial Carcinoma Cell. Journal of Urology, Vol 181 (4) April, 2009

190. Iverson P, McLeod D, Wirth M, See WA, Morris T; The CASODEX EPC program - 10 years of follow up; 27th Congress of the Scandinavian Association of Urology, June, 2009, Reykjavik, Iceland

191. Demand for Sexual Counseling Among Women Undergoing Radical Cystectomy for Bladder Cancer; Garg T, See WA, Langenstroer P, Guralnick M, Kressin M; North Central Section, Scottsdale, AZ, November, 2009

192. Laparoscopic Mesh Herniorraphy: Impact on Outcomes Associated with Radical Retropubic Prostatectomy; See WA, Neff D; North Central Section, Scottsdale, AZ, November, 2009

193. A comparison of Surgical Outcomes After Open Radical Prostatectomy Based on Case Order; Shridharani A, Langenstroer P, Jacobsohn K, See WA; Annual Wisconsin Urological Society Meeting, Madison, WI 2010

194. Duloxetine for the Treatment of Post-Prostatectomy Stress Urinary Incontinence; O'Connor RC, Vincent J, Neff D, Guise A, Langenstroer P, See WA, Guralnick M; Annual Wisconsin Urological Society Meeting, Madison, WI 2010

195. Demand for Sexual Counseling Among Women Undergoing Radical Cystectomy for Bladder Cancer; Garg T, See WA, Langenstroer P, Guralnick M, Kressin M; Annual Wisconsin Urological Society Meeting, Madison, WI 2010

196. Radical Retropubic Prostatectomy Outcomes in May-June versus July-August; Pagoria d, See WA; Annual Wisconsin Urological Society Meeting, Madison, WI 2010

197. Effects of P21 Down-Regulation on Urothelial Cell Viability Following BCG Treatment; Tonkin P, See WA; Annual Wisconsin Urological Society Meeting, Madison, WI 2010

198. Effect of Atorvastatin on the Biology of Bladder Cancer Cells Treated with Bacillus Calmette-Guerin. Garg T, See WA, American Urological Association Annual Meeting, San Francisco, CA May, 2010

199. The Effect of Statins on Continence Following Radical Retropubic Prostatectomy. See WA, Aberger M; North Central Section, Chicago, Il, September, 2010

200. Inhibition of Endothelial Nitric Oxide Synthase (eNOS) Results in Decreased Upregulation of p21 in 253J Tumor Cells Exposed to Live Bacillus Calmette-Guerin (BCG). Neff D A, See W A, Zhang G, Chen F, Annual Wisconsin Urological Society Meeting, Green Bay, WI 2011

201. Effect of Pentosan Polysulfate on Bacille-Calmette Guerin induced CEBP and p21 Gene Expression in Urothelial Carcinoma Cells. Khanh N P, Zhang G J, See W A, Annual Wisconsin Urological Society Meeting, Green Bay, WI 2011

202. Radical Retropubic Prostatectomy Outcomes in May - June versus July - August. Pagoria D, Aberger M, Langenstroer P, See W A. Annual Wisconsin Urological Society Meeting, Green Bay, WI 2011

1. Intussuscepted Vesico-Urethral Anastomosis (IVUA): A Reconstructive Technique for the Prevention of Post Prostatectomy Bladder Neck Contracture; Garg T, Payne R, See WA; North Central Section, Scottsdale, AZ, November, 2009